Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients

AIDS. 2004 Nov 19;18(17):2330-1. doi: 10.1097/00002030-200411190-00016.

Abstract

We compared the response to protease inhibitor-containing highly active antiretroviral therapy in 175 HIV-1 treatment-naive patients harbouring subtype B versus non-B. No difference in the proportion of patients with viral loads below 400 copies/ml was observed at month 24. However, there was a significant difference in the median CD4 cell increase at month 24. Whether this is caused by viral or immune factors warrants further investigation.

MeSH terms

  • Antiretroviral Therapy, Highly Active / methods*
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Protease Inhibitors / immunology
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / classification*
  • HIV-1 / immunology
  • Humans
  • Treatment Outcome
  • Viral Load

Substances

  • HIV Protease Inhibitors